Recent Trends in Medicaid Outpatient Prescription Drugs and Spending

More on the trends and the implications of recent federal policy actions ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

View in browser The independent source for health policy research, polling, and news. The independent source for health policy research, polling, and news. NEW & NOTEWORTHY KFF Examines Recent Trends in Medicaid Outpatient Prescription Drugs and Spending A new KFF issue brief describes recent trends in the number of Medicaid outpatient prescriptions and spending on those drugs, and also examines the implications of recent federal policy actions.   The analysis finds that net spending after rebates on Medicaid prescription drugs has grown substantially in recent years, rising by 46% from $31 billion in FY 2019 to $46 billion in FY 2024, due in part to high-cost drugs like GLP-1s and gene therapies. Both net spending per prescription and net spending per enrollee also grew over the period, while the number of prescriptions paid for by Medicaid only grew slightly over that period. Rebates from drug manufacturers – including those required by federal law for drugs covered by Medicaid – reduced gross Medicaid prescription drug spending by an average of 53% from FY 2019 to FY 2024. State supplemental rebates, which states negotiate directly with manufacturers, make up a growing share of all Medicaid drug rebates. It remains unclear how federal changes in the 2025 reconciliation law and recent federal prescription drug initiatives like "most-favored nation" drug pricing will affect future spending on prescription drugs.   Also available is KFF's new explainer on how Medicaid covers and pays for access to prescription drugs for one in five people in the U.S. More Trends Contact: Tammie Smith | 202.654.1410 | TammieS@kff.org  When citing our work, please note our legal name is KFF. We should be cited as KFF, a nonprofit health policy research, polling, and news organization. Our name is no longer the Kaiser Family Foundation.  Did someone forward this to you? Sign up for emails from KFF. This email was sent to awesomeblogger71.lificletter@blogger.com. Update your email preferences to choose the types of emails you receive. Or, permanently unsubscribe from all future emails. Need assistance? Email subscriptions@kff.org; do not reply to this email. The independent source for health policy research, polling, and news. KFF, 185 Berry Street, Suite 2000, San Francisco, CA 94107